Skip to main content

VolitionRx Limited

corporate_fare Company Profile

VolitionRx Limited

VNRX·NYSE·Life Sciences·CIK 0000093314

VolitionRx Limited is a multi-national epigenetics company developing a family of simple, easy-to-use, cost-effective blood tests. It holds patented technologies that use chromosomal structures, such as nucleosomes, and transcription factors as biomarkers in cancer and other diseases. Its tests detect characteristic changes that occur from the earliest stages of disease, enabling early detection and offering a way to monitor disease progression and a patient's response to treatment. The tests offered by Volition and its subsidiaries are designed to detect and monitor a range of life-altering diseases, including certain cancers and diseases associated with NETosis, such as sepsis. The company's key pillars of focus are: Nu.Q® Vet, cost-effective, easy-to-use blood tests for dogs and other companion animals, with the Nu.Q® Vet Cancer Test commercially available as a cancer screening test in dogs; Nu.Q® NETs, which detects diseases associated with NETosis such as sepsis; Nu.Q® Discover, a complete solution to profiling nucleosomes; Nu.Q® Cancer, covering screening, diagnosis and staging, therapy decision, planning and treatment, and monitoring response to treatment and disease progression, with a particular focus on lung cancer; and Capture-Seq™/Capture-PCR™, for isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. The company has grown from a single two-meter lab bench at the University of Namur in Belgium to a purpose-built 17,000 square foot lab and 10,000 square foot production facility in Gembloux, Belgium, an Innovation Lab in California, and offices in California, London and Nevada. It has a team of over 75 employees spanning a wide range of disciplines.

VolitionRx Limited (NYSE:VNRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for VNRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 2 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for VNRX spans 10-Q, 8-K.

Recent high-impact activity:

  • VolitionRx 10-Q: Going-Concern Doubt Persists With $2.4M Cash and NYSE Equity Deficiency
  • VolitionRx Q3 Revenue Up 157% to $1.6M; CEO Pay Cut to 50% of Original

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.73M
Net Income
-$23.36M
Op. Cash Flow
-$19.68M
Free Cash Flow
-$19.77M
Operating Income
-$21.74M
Cash & Equivalents
$1.12M
Total Debt
$6.71M
Debt / Equity
-0.20×
Net Margin
-13.52×
Shares Outstanding
125.78M sh
Source: 10-K · filed 2026-04-30 · accession 0001477932-26-002685

Short Interest & Short Volume

1.19 days to cover

FINRA reported short interest of 1,396,747 shares in VNRX as of the October 30, 2026 settlement, a 21.9% increase from the prior period — about 1.2 days to cover at its recent average daily volume. On November 20, 2026, 56.2% of VNRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,396,747 shares as of October 30, 2026
Change vs prior period▲ 21.9%
Days to cover1.19 at avg daily volume of 1,176,298
Daily short volume (FINRA facilities)56.2% of 597,342 shares on November 20, 2026
5-day average short volume52.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.1601 -1.23% today
52-week range · as of 2026-11-12 $0.1564 – $8.13
Market cap
$5.85M
Volume
1.2M (0.4× avg)
3-mo avg 3.1M
Live data · 2026-11-22 12:34 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VNRX - Latest Insights

VNRX
Nov 12, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1845
Real-time Price: $0.1601 info
Change: -$0.0244 (-13%) info
Market Cap: $5.849M info
VNRX
Nov 12, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1845
Real-time Price: $0.1601 info
Change: -$0.0244 (-13%) info
Market Cap: $5.849M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets